Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia

Gonzalez, Brian D.; Small, Brent J.; Cases, Mallory G.; Williams, Noelle L.; Fishman, Mayer; Jacobsen, Paul B.; Jim, Heather

doi:10.1002/cncr.31024

Cited by 47 publications

(39 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This beneficial effect occurred despite the study not selecting men for troublesome hot flushing or excluding men continuing to receive other medications for hot flushing. Yet, despite previous reports associating increased hot flushes with sleep disturbance (33) and reduced quality of life in men undergoing ADT (34,35), these benefits did not translate into a detectable improvement in overall quality-of-life scores. This disparity may be due to a lack of power because of the short duration of this study or because baseline quality of life was already relatively high in our cohort by comparison with other men with PCa (36).…”

Section: Hot Flushes and Quality Of Lifecontrasting

confidence: 78%

Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial

Russell

Hoermann

Cheung

et al. 2018

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Hot Flushes and Quality Of Lifecontrasting

confidence: 78%

Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial

Russell

Hoermann

Cheung

et al. 2018

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…2b, difficulty sleeping and hot flashes are on the edges of their respective symptom clusters. While we cannot demonstrate causality, it is known that the occurrence of hot flashes disrupts patients’ sleep 66,67 . If our findings are confirmed in an independent sample, future NAs can evaluate for causality and test interventions to reduce symptoms across clusters.…”

Section: Discussionmentioning

confidence: 59%

Network Analysis of the Multidimensional Symptom Experience of Oncology

Papachristou

Barnaghi

Cooper

et al. 2019

Sci Rep

119

View full text Add to dashboard Cite

Oncology patients undergoing cancer treatment experience an average of fifteen unrelieved symptoms that are highly variable in both their severity and distress. Recent advances in Network Analysis (NA) provide a novel approach to gain insights into the complex nature of co-occurring symptoms and symptom clusters and identify core symptoms. We present findings from the first study that used NA to examine the relationships among 38 common symptoms in a large sample of oncology patients undergoing chemotherapy. Using two different models of Pairwise Markov Random Fields (PMRF), we examined the nature and structure of interactions for three different dimensions of patients’ symptom experience (i.e., occurrence, severity, distress). Findings from this study provide the first direct evidence that the connections between and among symptoms differ depending on the symptom dimension used to create the network. Based on an evaluation of the centrality indices, nausea appears to be a structurally important node in all three networks. Our findings can be used to guide the development of symptom management interventions based on the identification of core symptoms and symptom clusters within a network.

show abstract

“…Cognitive impairment could also be associated with other known psychiatric adverse effects of ADT in men with PCa, such as depression [ 22 , 23 , 24 ] and reduced sleep quality [ 25 , 26 ]. Depression has been documented to increase in men with PCa, with a prevalence between 10% and 40% [ 27 , 28 ] that might be related to multiple factors, such as age, comorbidities, socioeconomic status, erectile dysfunction or the disorder itself [ 28 , 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

“…Some studies have concluded that poor sleep quality appears in approximately one-third of the men treated with ADT, but the underlying physiological mechanism is unclear [ 35 , 36 ]. Among other factors, it has been related to hot flashes, nicturia and emotional distress and to the pharmacological treatment of these adverse effects [ 26 , 37 , 38 , 39 ].…”

Section: Introductionmentioning

confidence: 99%

Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study

Sánchez-Martínez

Buigues

Navarro-Martínez

et al. 2021

Life

View full text Add to dashboard Cite

The relationship between cognitive decline and androgen deprivation therapy (ADT) under luteinizing hormone-releasing hormone (LHRH) analogues is unclear, and there is a scarcity of longitudinal studies considering the interaction between cognition, depressive symptoms and sleep quality in men with prostate cancer (PCa) treated with ADT. This study aimed to determine if there were differences in the scores obtained in cognitive assessment, depressive symptoms, and sleep quality after one year of ADT and determine the interrelations between sleep, mood, and cognitive status. A prospective longitudinal observational study was designed, in which a cohort of men (mean age was 70.8 years) newly treated with androgen-deprivation therapy was assessed in the first six months of treatment and 12 months later. Analysis of cognitive function by the Mini-Mental State Examination (MMSE) scores indicated a significant (p < 0.05) increase after one year of treatment and by the Brief Scale for Cognitive Evaluation (BCog) scores indicated no changes in the scores before and after one year of treatment. Analysis of depressive symptoms with the Geriatric Depression Scale and sleep quality with the Athens Insomnia Scale (AIS) scores showed significant (p < 0.05) changes after one year of treatment with ADT, with men describing more depressive symptoms and more sleep disturbances. No statistically significant differences were found in the cognitive performance between men with impaired sleep or depression results and those without them. Our study showed no clinical evidence of the relationship between ADT under luteinizing hormone-releasing hormone (LHRH) analogues and cognitive deterioration in 1-year follow-up, but there are impairments in the sleep quality in men with PCa undergoing ADT and an increase in depressive symptoms which has important implications for clinicians as they would impair quality of life and adherence to treatment.

show abstract

Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia

Cited by 47 publications

References 42 publications

Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial

Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial

Network Analysis of the Multidimensional Symptom Experience of Oncology

Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study

Contact Info

Product

Resources

About